Kodiak Sciences Inc
KOD
查看详细走势图
31.080USD
+3.630+13.22%
收盘 12/24, 13:00（美东）报价延迟15分钟
1.65B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+13.22%
5天
+15.24%
1月
+42.11%
6月
+760.94%
今年开始到现在
+212.36%
1年
+214.89%
查看详细走势图
TradingKey Kodiak Sciences Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Kodiak Sciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
8
位分析师
买入
评级
21.286
目标均价
-18.57%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Kodiak Sciences Inc亮点
亮点风险
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
估值低估
公司最新PE估值-4.97，处于3年历史低位
机构减仓
最新机构持股41.90M股，环比减少17.74%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值764.14K
活跃度增加
近期活跃度增加，过去20天平均换手率0.17
Kodiak Sciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Kodiak Sciences Inc简介
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
公司代码KOD
公司Kodiak Sciences Inc
CEOPerlroth (Victor)
网址https://kodiak.com/
常见问题
Kodiak Sciences Inc(KOD)的当前股价是多少？
Kodiak Sciences Inc(KOD)的当前股价是 31.080。
Kodiak Sciences Inc的股票代码是什么？
Kodiak Sciences Inc的股票代码是KOD。
Kodiak Sciences Inc股票的52周最高点是多少？
Kodiak Sciences Inc股票的52周最高点是29.490。
Kodiak Sciences Inc股票的52周最低点是多少？
Kodiak Sciences Inc股票的52周最低点是1.920。
Kodiak Sciences Inc的市值是多少？
Kodiak Sciences Inc的市值是1.65B。
Kodiak Sciences Inc的净利润是多少？
Kodiak Sciences Inc的净利润为-176.21M。
现在Kodiak Sciences Inc(KOD)的股票是买入、持有还是卖出？
根据分析师评级，Kodiak Sciences Inc(KOD)的总体评级为买入，目标价格为21.286。
Kodiak Sciences Inc(KOD)股票的每股收益（EPS TTM）是多少
Kodiak Sciences Inc(KOD)股票的每股收益（EPS TTM）是-4.119。
相关品种
